Healthcare, Pharma & Life Sciences

Sobi's Gamifant Data Get Best Poster Nod at HS2026 in Rotterdam

Stockholm – September 24, 2026 -- Sobi (STO: SOBI) will present new clinical data on its rare-disease drug Gamifant (emapalumab) at the 2026 Annual Meeting of the Histiocyte Society (HS2026), running September 26-29 in Rotterdam, the Netherlands, with a pooled survival analysis nominated for the meeting's top poster prize.

Pooled transplant-survival analysis earns Robert J. Arceci Prize nomination

The accepted abstract set includes a new pooled analysis of pre- and post-transplant survival outcomes in primary haemophagocytic lymphohistiocytosis (HLH), drawing on data across three prospective trials. Sobi said the analysis was selected as one of the ten highest-scoring poster abstracts at HS2026 and has been nominated for the Robert J. Arceci Prize for Best Poster.

Sectra One Cloud Goes Live at Northeast Georgia Medical Center

Linköping – September 24, 2026 -- Northeast Georgia Medical Center has gone live with Sectra's cloud-based enterprise imaging platform, Sectra One Cloud, under a five-year contract covering an expected annual imaging volume of around 850,000 exams.

Hospital deploys radiology, breast imaging and cardiology modules in first rollout phase

The Gainesville-based flagship hospital of Northeast Georgia Health System initially activated three specialty modules on the unified platform, allowing clinicians across sites to view, share and report on patient studies from a single system rather than separate applications tied to each specialty.

Richard Wright, Executive Director of Imaging Services for Northeast Georgia Medical Center, said the consolidated workflow has reduced steps between viewing studies and finalizing reports, and enables clinicians at different sites to consult on the same case.

Daewoong Completes 104-Patient Phase 2 Enrollment for IPF Drug Bersiporocin

Image
Daewoong Completes 104-Patient Phase 2 Enrollment for IPF Drug Bersiporocin

Barcelona – September 24, 2026 -- Daewoong Pharmaceutical has completed enrollment of 104 idiopathic pulmonary fibrosis (IPF) patients in its global Phase 2 trial of Bersiporocin (DWN12088), with top-line results now expected in the first half of 2027.

Trial spans South Korea and the US with balanced enrollment

Of the 104 patients, 55 (52.9%) were enrolled in South Korea and 49 (47.1%) in the United States. The company presented full baseline patient characteristics at the European Respiratory Society (ERS) Congress 2026 in Barcelona on September 6, following interim data shared earlier at KATRDIC 2025.

ULC Brings Gary Brecka Longevity Tour to Boulder, Denver Oct. 4

Image
ULC Brings Gary Brecka Longevity Tour to Boulder, Denver Oct. 4

Boulder, Colo. – September 24, 2026 -- Ultimate Longevity Center (ULC), a Sequel Brands franchise with more than 300 territories sold globally, will host two free live events with human performance expert Gary Brecka in Colorado on Sunday, October 4.

ULC schedules back-to-back Colorado events after strong Los Angeles turnout

Brecka will appear at Macky Auditorium in Boulder at 10:30 AM MT and at the Fillmore Auditorium in Denver at 3:30 PM MT, both hosted by ULC in collaboration with Ultimate Human. The dates follow his August appearance at Peacock Theater in Los Angeles, which drew thousands of attendees.

Astellas Doses First Patient in Phase 3 Lung Cancer Trial of Setidegrasib

Image
Astellas Doses First Patient in Phase 3 Lung Cancer Trial of Setidegrasib

Tokyo – September 24, 2026 -- Astellas Pharma Inc. (TSE: 4503) has dosed the first patient in a Phase 3 study evaluating setidegrasib, an investigational KRAS G12D-targeted protein degrader, against docetaxel in previously treated non-small cell lung cancer (NSCLC) patients carrying the KRAS G12D mutation.

Trial targets patients who progressed on chemotherapy and checkpoint inhibitors

The randomized, open-label study will enroll approximately 356 patients across multiple countries whose locally advanced or metastatic NSCLC has progressed after platinum-based chemotherapy and checkpoint inhibitor therapy. Dual primary endpoints are progression-free survival, assessed by blinded independent central review, and overall survival.

Bladder Cancer Treatment Market to Hit $11.33B by 2034

Image
Bladder Cancer Treatment Market to Hit $11.33B by 2034

Pune, India – September 24, 2026 -- The global bladder cancer treatment market was valued at $5.13 billion in 2025 and is projected to reach $11.33 billion by 2034, expanding at a 9.2% compound annual growth rate, according to a new analysis from Maximize Market Research.

Immunotherapy and antibody-drug conjugates drive treatment shift

Adoption of immune checkpoint inhibitors, antibody-drug conjugates (ADCs), and FGFR inhibitors is accelerating across non-muscle-invasive and muscle-invasive bladder cancer segments. Pharmaceutical companies are directing R&D spend toward intravesical drug delivery, gene therapy, and biomarker-driven precision oncology to improve outcomes for recurrent and metastatic urothelial cancer patients.

Viking Therapeutics Launches $400M Dual Offering to Fund Obesity Drug Pipeline

Image
Viking Therapeutics Launches $400M Dual Offering to Fund Obesity Drug Pipeline

San Diego – September 24, 2026 -- Viking Therapeutics plans to raise $400 million through simultaneous public offerings of $200 million in common stock and $200 million in convertible senior notes due 2032, with proceeds earmarked for its obesity drug pipeline.

Viking structures two independent capital raises with built-in flexibility

The biopharmaceutical company intends to grant underwriters a 30-day option to purchase an additional $30 million in common stock and a separate 30-day option for up to $30 million more in notes to cover over-allotments. Completion of one offering is not contingent on the other, giving Viking flexibility if market conditions shift. Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC are serving as joint book-running managers for both transactions.

ULC Franchise Tops 300 Territories, Launches 50-Site Australia Expansion

Image
ULC Franchise Tops 300 Territories, Launches 50-Site Australia Expansion

Newport Beach – September 24, 2026 -- Ultimate Longevity Center (ULC) has surpassed 300 sold territories worldwide after unveiling a 50-location Australian franchise rollout, with the first center confirmed for Sydney's Double Bay in Q1 2027.

ULC crosses 300 global territories within a year of launching U.S. franchise sales

The longevity and human-optimization brand, built by Sequel Brands founder Anthony Geisler alongside human biologist Gary Brecka and precision health platform Lifeforce, has sold more than 275 territories across the United States since opening franchise sales in 2026, including 200 in its first four months. The newly announced 50-center Australian network pushes the brand's global footprint past 300 territories.

AmeriHealth Caritas Expands HealthSherpa Deal to Billing, Reconciliation

Sacramento, Calif. – September 24, 2026 -- HealthSherpa is expanding its multi-year partnership with AmeriHealth Caritas to include Marketplace Operations, its enrollment, premium billing and reconciliation platform for individual and family health plans sold on and off the Health Insurance Marketplace.

AmeriHealth Caritas will use the platform to reconcile enrollments and collect premiums

Under the expanded deal, AmeriHealth Caritas will process and reconcile enrollments directly with the Health Insurance Marketplace, collect subsidy and member premiums, and resolve data discrepancies before they affect member bills or coverage status.

BPD Health Rebrands, Positions Itself as Healthcare Growth Partner

Image
BPD Health Rebrands, Positions Itself as Healthcare Growth Partner

Boca Raton, Fla. – September 24, 2026 -- BPD Health has launched a new brand identity, "It's Good to Grow," repositioning the two-decade-old healthcare marketing firm as a strategic growth partner for hospitals, life sciences firms and health innovators.

BPD traces its evolution from an advertising agency to a growth strategy firm

The company has operated under three names over more than 20 years: BPD Advertising, BPD Healthcare, and now BPD Health. Each iteration marked an expansion of scope, moving from healthcare marketing services toward broader strategic growth advisory work for health systems, life sciences companies, healthcare associations and consumer health brands.